GDRX icon

GoodRx Holdings

4.63 USD
-0.03
0.64%
At close Apr 30, 4:00 PM EDT
After hours
4.66
+0.03
0.65%
1 day
-0.64%
5 days
-0.22%
1 month
4.99%
3 months
-6.46%
6 months
-27.43%
Year to date
1.54%
1 year
-34.79%
5 years
-90.83%
10 years
-90.83%
 

About: GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Employees: 738

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

253% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $1.2M

35% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 34

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

11% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 46

1% more funds holding

Funds holding: 165 [Q3] → 166 (+1) [Q4]

13.69% less ownership

Funds ownership: 144.08% [Q3] → 130.39% (-13.69%) [Q4]

36% less capital invested

Capital invested by funds: $986M [Q3] → $632M (-$354M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5.50
19%
upside
Avg. target
$6.25
35%
upside
High target
$7
51%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Wells Fargo
Stan Berenshteyn
30% 1-year accuracy
3 / 10 met price target
51%upside
$7
Overweight
Maintained
29 Apr 2025
Truist Securities
Jailendra Singh
34% 1-year accuracy
12 / 35 met price target
19%upside
$5.50
Hold
Maintained
10 Apr 2025

Financial journalist opinion

Based on 5 articles about GDRX published over the past 30 days

Positive
Zacks Investment Research
15 hours ago
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth
GoodRx (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth
Neutral
Business Wire
3 weeks ago
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business out.
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call
Neutral
Zacks Investment Research
3 weeks ago
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
Positive
PYMNTS
3 weeks ago
GoodRx Launches eCommerce Offering for Retail Pharmacies
GoodRx has launched an eCommerce experience for retail pharmacies in collaboration with grocery chain Hy-Vee. With this new tool, announced Thursday (April 3), GoodRx will check inventories when a consumer searches for medication, determining whether it's available at the pharmacy and can be purchased online.
GoodRx Launches eCommerce Offering for Retail Pharmacies
Neutral
Business Wire
3 weeks ago
GoodRx Introduces New E-commerce Experience for Retail Pharmacies
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee. Now, when a person searches for their medication on GoodRx and selects Hy-Vee as their preferred pharmacy, the system will check for medication inventory, validate.
GoodRx Introduces New E-commerce Experience for Retail Pharmacies
Positive
Seeking Alpha
1 month ago
GoodRx: Great Value For Patient Investors (Upgrade)
GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers.
GoodRx: Great Value For Patient Investors (Upgrade)
Neutral
Business Wire
1 month ago
GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and man.
GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement
Neutral
Business Wire
1 month ago
GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today released a new report, The Prescription Drug Gender Divide, detailing how women shoulder a significantly greater out-of-pocket cost burden than men. The data shows that in 2024, women spent $8.8 billion – or 30% – more than men on out-of-pocket prescription costs. Combined with the common responsibilities of managing a career, family planning, and caregiving, women are le.
GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending
Neutral
Benzinga
2 months ago
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
Neutral
Seeking Alpha
2 months ago
GoodRx Holdings, Inc. (GDRX) Q4 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - Bank of America Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2024 Earnings Call.
GoodRx Holdings, Inc. (GDRX) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™